LinkedIn
WebsiteIntroduction
ENVERIC BIOSCIENCES INC (NASDAQ: ENVB) is a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics for mental health disorders. Leveraging its proprietary Psybrary™ discovery platform, the company has built an intellectual property portfolio targeting conditions such as depression, anxiety, and addiction.
| Metric | Value |
|---|---|
| Price (2025-09-17) | $0.6544 |
| Change (%) | -28.48% |
| Volume | 414,114 |
| Exchange | NASDAQ |
| 52-Week Range | $0.6400 – $124.8750 |
| Market Cap | $2.12 million |
Corporate Structure
Headquartered in Naples, Florida, with offices in Cambridge, Massachusetts, and Calgary, Alberta, ENVERIC employs between 11 and 50 staff. Executive leadership includes:
• Joseph Tucker, Ph.D., Chief Executive Officer;
• Luigi Facchini, Ph.D., Chief Scientific Officer;
• Kevin Coveney, CPA, Chief Financial Officer;
• Jillian Hagel, Ph.D., Vice President of Innovation;
• Additional senior officers overseeing operations, R&D, and business development.
Neuroplastogen by Maxim Potkin ❄
Recent Developments
On September 2, 2025, the company filed a Form 8-K reporting the exercise of warrants that generated $2.2 million in gross proceeds. The proceeds are intended to support the advancement of EB-003, the lead neuroplastogen candidate designed to promote recovery in PTSD, treatment-resistant depression, and anxiety disorders without hallucinogenic effects. On August 29, 2025, ENVERIC filed two additional Form 8-Ks covering corporate changes, reflecting amendments to its capital structure and ongoing strategic initiatives.
Financial and Strategic Analysis
Trading at $0.6544 on September 17, 2025, the stock has experienced a decline of 28.48% on that day amid lower liquidity than its 250,950-share average volume. Key financials (trailing twelve months as of mid-September) include:
• Net loss of $9.94 million;
• Total cash of $2.85 million against a debt/equity ratio of 4.57%;
• Price/Book ratio of 1.36 and an enterprise value of $120,530;
• Beta of 0.37, indicating lower volatility relative to the S&P 500.
Strategically, ENVERIC is advancing EB-003 toward an IND submission, highlighting its dual-receptor mechanism (5-HT2A and 5-HT1B). The company's EVM401 series explores mescaline-derived phenylalkylamines for applications including opioid withdrawal and ADHD, although the primary focus remains on EB-003’s clinical progression. Funding from warrant exercises is expected to extend the runway for preclinical and regulatory milestones.
Market Position and Industry Context
ENVERIC operates within the mental health therapeutics market, which is characterized by a demand for non-hallucinogenic, fast-acting treatments. The company’s small-molecule approach contrasts with competing psychedelic therapies that rely on controlled dosing in clinical settings. ENVERIC’s intellectual property and licensing strategy involves out-licensing secondary candidates to non-conflicting partners, aiming to broaden its footprint without overextending R&D resources. With a market cap of approximately $2.12 million, ENVERIC functions as a micro-cap participant in neuropsychiatric drug development, subject to clinical outcomes, funding availability, and regulatory review timelines.
tl;dr
ENVERIC raised $2.2 million on September 2, 2025, through warrant exercises, intended for the development of EB-003, its lead non-hallucinogenic neuroplastogen. Trading at $0.6544 on September 17, 2025, the company reported a $9.94 million net loss (TTM) with $2.85 million in cash and low leverage. Key upcoming catalysts include an IND submission for EB-003 and progress updates on preclinical assets.
